Abstract
G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential. One in particular that has been gaining attention in recent times is that of GPCR ligands that bind to allosteric sites on the receptor distinct from the orthosteric site of the endogenous ligand. As therapeutics, allosteric ligands possess many theoretical advantages over their orthosteric counterparts, including more complex modes of action, improved safety, more physiologically appropriate responses, better target selectivity, and reduced likelihood of desensitisation and tachyphylaxis. Despite these advantages, the development of allosteric ligands is often difficult from a medicinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR. The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free fatty acid sensitive GPCRs.
Keywords: Allosteric ligand, FFA1-3, free fatty acid, GPCR, GPR84, GPR120 orthosteric ligand
Current Topics in Medicinal Chemistry
Title:The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs
Volume: 13 Issue: 1
Author(s): Brian D. Hudson, Trond Ulven and Graeme Milligan
Affiliation:
Keywords: Allosteric ligand, FFA1-3, free fatty acid, GPCR, GPR84, GPR120 orthosteric ligand
Abstract: G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential. One in particular that has been gaining attention in recent times is that of GPCR ligands that bind to allosteric sites on the receptor distinct from the orthosteric site of the endogenous ligand. As therapeutics, allosteric ligands possess many theoretical advantages over their orthosteric counterparts, including more complex modes of action, improved safety, more physiologically appropriate responses, better target selectivity, and reduced likelihood of desensitisation and tachyphylaxis. Despite these advantages, the development of allosteric ligands is often difficult from a medicinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR. The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free fatty acid sensitive GPCRs.
Export Options
About this article
Cite this article as:
D. Hudson Brian, Ulven Trond and Milligan Graeme, The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs, Current Topics in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1568026611313010004
DOI https://dx.doi.org/10.2174/1568026611313010004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance
Current Pharmaceutical Design H19: A Vital Long Noncoding RNA in the Treatment of Diabetes and Diabetic Complications
Current Pharmaceutical Design Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Antioxidant Properties and Medicinal Uses of Some Crataegus Spp. (Hawthorn) Including <i>C. meyeri</i> and <i>C. pontica</i>
Current Nutrition & Food Science Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets SGLT-2i and Cardiovascular Prognosis
Current Pharmaceutical Design Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Intestinal Uptake of Insulin Nanoparticles: Facts or Myths?
Current Pharmaceutical Biotechnology Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond
Current Pharmaceutical Design Impact of Physical Activity on Gestational Weight Gain in Overweight and Obese Pregnant Women: A Meta-Analysis
Current Women`s Health Reviews Proteomic Analysis of Aqueous Humor Proteins Associated with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Current Proteomics Dietary Factors Influencing Magnesium Absorption in Humans
Current Nutrition & Food Science Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Role of Cytokines and Trophic Factors in the Pathogenesis of Diabetic Retinopathy
Current Diabetes Reviews Transient Tachypnea of the Newborn: The Treatment Strategies
Current Pharmaceutical Design